Telomir Pharmaceuticals names Andriy Mushak fractional CFO, replacing Alan Weichselbaum
Share
Listen to the news
Telomir Pharmaceuticals names Andriy Mushak fractional CFO, replacing Alan Weichselbaum
  • Telomir Pharmaceuticals named Andriy Mushak fractional CFO effective June 6, 2026.
  • Alan Weichselbaum will step down as CFO on June 6, 2026; departure not tied to any disputes over operations or policies.
  • Mushak is a CPA; partner at LMAM Consulting Group leading SEC reporting, financial statements, technical accounting, and M&A support.
  • He previously spent more than a decade at Baker Tilly US in audit, most recently as a senior manager.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-027752), on June 08, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending